Literature DB >> 21947930

Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosis.

Sandhya Hegde1, Radha Annamalai, Jyotirmay Biswas.   

Abstract

Entities:  

Year:  2011        PMID: 21947930      PMCID: PMC3302999          DOI: 10.1007/s12348-011-0041-y

Source DB:  PubMed          Journal:  J Ophthalmic Inflamm Infect        ISSN: 1869-5760


× No keyword cloud information.

Introduction

Sarcoid uveitis is usually a presumptive diagnosis based on the simultaneous presence of uveitis and clinicoradiographic or histological findings of sarcoidosis. Mycophenolate mofetil (MMF) is an anti-metabolite, selectively aimed at affecting lymphocytic action [1, 2]. It has been proven to be safe and effective in post organ transplant [3] and seems to have similar efficacy in non-infectious uveitis [4]. In patients who are corticosteroid resistant or require an unacceptable dose of corticosteroids to maintain remission, additional immunosuppression is used, including methotrexate, azathioprine, and MMF. We report an uncommon case of a 34-year-old male of sarcoid uveitis who developed extensive herpes zoster while on treatment with MMF.

Case report

A 34-year-old male was referred to our hospital with a history of decreased vision as a result of recurrent bilateral posterior uveitis. He had repeated recurrences in spite of systemic corticosteroid therapy. At presentation to us, his best corrected visual acuity (BCVA) was 6/36, N36 in the right eye and 6/9, N6 in the left eye. Slit lamp examination revealed a normal anterior chamber and complicated cataract in the right eye. On fundus evaluation, both eyes revealed bilateral disc edema and vitritis and exudates in the macula in the right eye. He was not a known diabetic. Laboratory investigations for tuberculosis, collagen vascular diseases, and other infectious etiologies including human immunodeficiency virus were within normal limits except serum angiotension converting enzyme values which were borderline high. Treatment was initiated with MMF (2 g/day) [5] along with tapering doses of oral prednisolone (1 mg/kg/day) in view of the recurrent nature of the uveitis. The lesions resolved completely with treatment. He underwent cataract surgery in both eyes 6 months later under cover of MMF (1 g/day) and systemic corticosteroids. Postoperative period was uneventful. Four months later, he had a recurrence of fundus lesions and was started on oral prednisolone (60 mg/day) and his MMF dose was doubled to 2 g/day by his local ophthalmologist. He came to us within a month with extensive skin lesions over his right neck and upper thoracic region which was clinically diagnosed as herpes zoster (Fig. 1). MMF was stopped and oral acyclovir (400 mg five times per day) was started. With treatment, the herpetic lesions resolved and his ocular status was stable with BCVA 6/12, N12 in the right eye and 6/6, N6 in the left eye.
Fig. 1

Clinical photograph showing extensive herpes zoster involvement in a 35-year-old patient

Clinical photograph showing extensive herpes zoster involvement in a 35-year-old patient

Discussion

MMF is useful in various ocular inflammatory conditions. Its advantage is its potent corticosteroid sparing effect and relatively benign side effects such as gastrointestinal disturbances, alopecia, and transient leucopenia [6, 7].Our patient showed a good response to combined treatment with MMF (2 g/day) and prednisolone (1 g/day). But he developed extensive herpes zoster after 10 months of treatment requiring discontinuation of the drug. Opportunistic infections have been rarely reported in sarcoid uveitis in spite of the immune dysregulation noted in these patients [8]. Herpes zoster is known to occur in post organ transplant cases who are on multiple immunosuppressive drugs usually around the 9th to the 12th month as was seen in our patient [9]. But a multicentre randomized controlled trial of MMF in doses of 2–3 g/day for renal transplant patients did not report even a single case of herpes zoster [10]. Higher doses of MMF can have an atypical and disseminated varicella infection [11]. But herpes zoster as an opportunistic infection with oral steroids is rare and generally mild and self-limiting [12]. There are no reports of such extensive herpes lesions in otherwise immunocompetent individuals. Thus, in our patient, a cumulative immunosuppressive effect may have been the reason for such an extensive involvement with herpes zoster. A serology done prior to treatment is of no help as patients with varicella antibodies have also been found to develop full-borne varicella infection [13]. With discontinuation of MMF and appropriate anti-viral therapy, the lesions resolved completely. Studies like SITE study [14] have shown that the overall risk of opportunistic infections with the use of long-term immunosuppressives is very low. Our case highlights the fact that reactivation of herpes zoster can occur with therapeutic doses of MMF for uveitis in otherwise healthy immunocompetent adults. It does not necessarily prove that other such opportunistic infections may be a possible side effect with MMF treatment. It would be wise to enlighten the patients regarding this possibility and allow for early recognition and treatment.
  9 in total

1.  Herpes zoster after lung transplantation: incidence, timing, and outcome.

Authors:  Leonardo Fuks; David Shitrit; Benjamin D Fox; Anat Amital; Yael Raviv; Ilana Bakal; Mordechai R Kramer
Journal:  Ann Thorac Surg       Date:  2009-02       Impact factor: 4.330

Review 2.  Mycophenolate mofetil.

Authors:  J J Lipsky
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 3.  [Opportunistic infections and sarcoidosis].

Authors:  N Girard; V Cottin; A Hot; B Etienne-Mastroianni; C Chidiac; J F Cordier
Journal:  Rev Mal Respir       Date:  2004-12       Impact factor: 0.622

4.  Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil.

Authors:  W S Rothwell; J M Gloor; B Z Morgenstern; D S Milliner
Journal:  Transplantation       Date:  1999-07-15       Impact factor: 4.939

5.  Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients.

Authors:  Kirsten Siepmann; Matthias Huber; Nicole Stübiger; Christoph Deuter; Manfred Zierhut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-15       Impact factor: 3.117

6.  Mycophenolate mofetil therapy for inflammatory eye disease.

Authors:  Jennifer E Thorne; Douglas A Jabs; Faqir A Qazi; Quan Dong Nguyen; John H Kempen; James P Dunn
Journal:  Ophthalmology       Date:  2005-08       Impact factor: 12.079

7.  Management of autoimmune retinopathies with immunosuppression.

Authors:  Henry A Ferreyra; Thiran Jayasundera; Naheed W Khan; Shirley He; Ying Lu; John R Heckenlively
Journal:  Arch Ophthalmol       Date:  2009-04

8.  Mycophenolate mofetil therapy for sarcoidosis-associated uveitis.

Authors:  Pooja Bhat; Rene A Cervantes-Castañeda; Priyanka P Doctor; Fahd Anzaar; C Stephen Foster
Journal:  Ocul Immunol Inflamm       Date:  2009 May-Jun       Impact factor: 3.070

9.  A pilot study of oral corticosteroid therapy for idiopathic esophageal ulcerations associated with human immunodeficiency virus infection.

Authors:  C M Wilcox; D A Schwartz
Journal:  Am J Med       Date:  1992-08       Impact factor: 4.965

  9 in total
  3 in total

Review 1.  Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases.

Authors:  Luis Malpica; Stephan Moll
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

3.  Treatment of paraneoplastic cerebellar degeneration.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.